Jingyuan Wang

Dr. Jingyuan Wang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
HAHIROYUKI ARAI
HIROYUKI ARAI
NGNishant Gandhi
Nishant Gandhi
FBFrancesca Battaglin
Francesca Battaglin
JWJingyuan Wang
Jingyuan Wang
SASandra Algaze
Sandra Algaze
HLHeinz-Josef Lenz
Heinz-Josef Lenz
Background: In patients with colorectal cancer (CRC), the therapeutic effects of conventional immune checkpoint inhibitors targeting the adaptive immune system are largely limited to those with microsatellite instability-high tumors. Meanwhile, new immunotherapies targeting the innate immune system are attracting increasing attention. CD47 is a representative innate immune checkpoint involved in the evasion of tumor cell phagocytosis by macrophages. This large-scale study comprehensively examined the molecular significance of CD47 gene expression in CRC. Methods: We analyzed the next-generation sequencing data of DNA and RNA from 14,287 CRC cases included in the data set of a commercial Clinical Laboratory Improvement Amendments-certified laboratory (Caris Life Sciences). The cases were divided into two groups based on the median value of CD47 gene expression levels. The molecular and immune profiles between the groups were compared, and the relationship between CD47 expression and survival outcomes was further examined. Results: In CD47-high tumors, the proportion of consensus molecular subtypes 1 and 4 was significantly higher than in CD47-low tumors. The expression levels of damage-associated molecular pattern-related genes showed a positive correlation with CD47 expression levels. Major oncogenic pathways, such as mitogen-activated protein kinase, phosphoinositide 3-kinase, angiogenesis, and transforming growth factor beta, were significantly activated in CD47-high tumors. Additionally, the expression levels of a panel of adaptive immune checkpoint genes and estimates of immune cells constituting the tumor microenvironment (TME) were significantly higher in CD47-high tumors. Conclusions: CD47 expression in CRC was associated with the activation of several oncogenic pathways and an immune-engaged TME. Our findings may provide valuable information for considering new therapeutic strategies targeting innate immune checkpoints in CRC.

11 September 2026 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YLYutong Liu
Yutong Liu
YZYanjing Zhu
Yanjing Zhu
SYShan Yu
Shan Yu
XXXiaojing Xu
Xiaojing Xu
YYYiyi Yu
Yiyi Yu
TLTianshu Liu
Tianshu Liu
While KRAS mutations are pivotal oncogenic drivers in colorectal cancer (CRC), their clinical and biological heterogeneity across KRAS subtypes remains poo

15 October 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
JWJingyuan Wang
Jingyuan Wang
JXJoanne Xiu
Joanne Xiu
AFAlex P Farrell
Alex P Farrell
FBFrancesca Battaglin
Francesca Battaglin
HAHIROYUKI ARAI
HIROYUKI ARAI
HLHeinz-Josef Lenz
Heinz-Josef Lenz
Purpose Tumor mutation burden (TMB) is a predictive biomarker for immune checkpoint inhibitor (ICI) treatment in mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) cancers. We aimed to characterize specific molecular features of dMMR/MSI-H gastrointestinal (GI) tumors with a range of TMB levels.Experimental design A total of 2272 GI tumors tested as dMMR/MSI-H were analyzed using next-generation sequencing (NGS) and immunohistochemistry (IHC) (Caris Life Sciences, Phoenix, Arizona, USA). Molecular features were compared in four groups (TMB <10 vs 10–20 vs 20–50 vs ≥50 mutations/Mb) using Fisher’s exact test or χ 2 and adjusted for multiple comparisons by Benjamini-Hochberg. The impact of TMB on tumor immune environment and clinical outcomes of ICI treatment was analyzed using the TCGA and PUCH cohorts, respectively.Results Tumors with TMB over 10, 20, 50 mutations/Mb were observed in 95.38%, 86.05% and 14.48%, respectively, in the dMMR/MSI-H GI cohort. Mutation rates in MSH3, RNF43, KMT2D, MSH6, BCL9, CIC, KMT2C, FANCM, JAK1, PRKDC, FLCN, PTEN, PTCH1, SPEN, SETD2, and NBN were the highest in the dMMR/MSI-H GI tumors with TMB over 50 mutations/Mb, while TP53 mutations showed the highest rate in TMB below 10 mutations/Mb (all Padj <0.01). Among them, RNF43 and PTCH1 mutations were identified as the positive predictors for survival benefit from ICI treatment, while TP53 was a negative predictor. We further combined the mutational status of RNF43, PTCH1, and TP53, and found TP53-wild-type patients with any mutations in RNF43 and PTCH1 showed a superior clinical benefit for DCB (100% vs 35.7%, p=0.006), PFS (NR vs 3.17 months, HR=0.16, 95% CI 0.046 to 0.57, p=0.0045), and OS (NR vs 12.37 months, HR=0.15, 95% CI 0.033 to 0.67, p=0.015) patients with RNF43/PTCH1-WT or TP53-MT.Conclusions This is the largest study to investigate the distinct molecular landscape of dMMR/MSI-H GI cancers with different levels of TMB. These data may inform our understanding of the efficacy of ICI in the dMMR/MSI-H GI tumors.